Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment With Tigulixostat in Gout Patients With Hyperuricemia

NCT05586958 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT05586958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment With Tigulixostat in Gout Patients With Hyperuricemia
Lead sponsor
LG Chem
Phase
Phase 3
Overall status
Completed
Start date
October 25, 2022
Completion date
December 16, 2024
Enrollment
354 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

gout, gout flare, hyperuricemia, tophi